Fintel reports that on January 10, 2025, BTIG initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation.

Energy & Infrastructure Analyst Lewis and Fixed Income Strategist Malley discuss bitcoin mining trends and themes across the capital ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Palo Alto Networks (NasdaqGS:PANW) from Buy to ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...

BTIG analyst Justin Zelin lowered the firm’s price target on Jasper Therapeutics (JSPR) to $64 from $90 and keeps a Buy rating on the shares ...

BTIG Chief Market Technician Jonathan Krinsky thinks the market can “continue to make upside progress” into year-end and sees a new all-time high for the S&P 500 (SPX) above 6,100. However ...

Last week, BTIG analyst Jake Fuller reiterated a Buy rating on Uber Technologies (UBER) stock with a price target of $90. The analyst remains bullish on the ride-hailing company but expects its Q4 ...

The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...

BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...

BTIG initiated coverage of Cartesian Therapeutics (RNAC) with a Buy rating and $42 price target Cartesian is pioneering the field of mRNA-based CART cell therapies for autoimmune disorders ...

Apple (AAPL) shares are up about 8% over the past month. But BTIG chief market technician Jonathan Krinsky is warning ...

According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...